CareDx Details Transplant+ Roadmap, AlloHeme Timeline, and 2026 Outlook at Raymond James Conference

CareDx (NASDAQ:CDNA) executives outlined the company’s transplant-focused strategy, caller fiscal performance, and 2026 priorities during remarks astatine the Raymond James Institutional Investor Conference. Chief Operating Officer and precocious appointed Chief Financial Officer Keith Kennedy and Chief Commercial Officer Jessica Meng described CareDx’s presumption successful coagulated organ transplant diagnostics and services, and provided further item astir pipeline plans nether the company’s “Transplant+” roadmap.

Kennedy reiterated CareDx’s stated imaginativeness that “every diligent receives the transplant they request to unrecorded longer, fuller lives,” and described the objective discourse driving ongoing request for monitoring. He said determination are astir 100,000 patients connected the U.S. transplant waiting database and that a caller diligent is added each 8 to 10 minutes. Following coagulated organ transplant, patients are monitored regularly—often monthly oregon quarterly—for aboriginal signs of rejection, erstwhile involution is much apt to sphere graft function.

→ Uber and Joby Aviation Team Up: Game Changer oregon Hype?

CareDx described itself arsenic the marketplace person successful coagulated organ transplantation, stating it has performed much than 1 cardinal tests and astir 200,000 tests successful 2025. The institution said it supports much than 200 transplant centers successful the U.S., representing astir 80% of each transplant centers, and offers investigating services, software, diligent solutions, and distributed trial kits crossed kidney, liver, heart, lung, and multi-organ transplants.

Kennedy highlighted CareDx’s broader footprint beyond diagnostics, including:

• More than 200,000 next-generation sequencing-based HLA typing kits sold annually, offered successful implicit 100 countries

• A transplant-focused pharmacy concern serving patients successful each 50 states, with much than 150,000 transplant prescriptions filled annually

• Software products supporting medicine adherence absorption and prime reporting, which the institution said are integrated into objective workflows astatine transplant centers

→ Costco Wholesale: Buy Now, Get Paid Later arsenic Cash and Returns Build

Kennedy described AlloSure arsenic a non-invasive humor trial that measures donor-derived cell-free DNA to observe wounded to the transplanted organ and measure rejection risk. He said elevated donor-derived cell-free DNA whitethorn bespeak imaginable graft wounded oregon rejection, and positioned AlloSure arsenic the archetypal clinically validated and commercially scaled donor-derived cell-free DNA trial utilized routinely crossed coagulated organ transplants.